BRII-B Buys Back 42,000 Shares, Lifts Treasury Stock to 16.34 Million

Bulletin Express11-11

Brii Biosciences Limited (BRII-B) disclosed that it repurchased 42,000 ordinary shares on 11 November 2026 through on-market transactions on the Hong Kong Stock Exchange. The repurchase was executed at prices ranging from HKD 1.045 to HKD 1.055 per share, representing a volume-weighted average cost of HKD 1.0482 and an aggregate outlay of HKD 0.04 million.

Following the transaction: • Issued shares (excluding treasury shares) decreased by 0.0058 % to 719.51 million. • Treasury shares increased to 16.34 million. • Total issued share capital remained unchanged at 735.86 million shares, as the repurchased stock is being held in treasury and has not been cancelled.

The buyback forms part of the mandate approved on 16 June 2026, which allows BRII-B to repurchase up to 72.19 million shares. Cumulative repurchases under this mandate now stand at 3.62 million shares, equivalent to 0.50 % of the issued share base as at the authorisation date.

Under Hong Kong Listing Rule 10.06, the company is restricted from issuing new shares or disposing of treasury shares for 30 days after the repurchase, setting a moratorium period through 11 December 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment